Form 4: Abbott Laboratories Director Robert Alpern Reports Acquisition of Common Shares

Director Robert Alpern reports acquisition of 1,866 common shares of Abbott Laboratories on April 26, 2024, through restricted stock units.

Summary

• Robert J. Alpern, a director of Abbott Laboratories, reported a transaction on April 26, 2024.
• Alpern acquired 1,866 common shares without par value at a price of $0.
• This acquisition was through restricted stock units awarded under the Abbott Laboratories 2017 Incentive Stock Program.
• Following the transaction, Alpern beneficially owns 39,163 common shares.
• These restricted stock units will be paid in Abbott common shares on a one-to-one basis upon separation from service, death, or a change in control.
• The report was signed by Jessica H. Paik, Attorney-in-Fact, on April 30, 2024.

Sentiment

Score: 6

Explanation: Neutral sentiment as it's a routine disclosure of stock units granted as part of a compensation plan. The acquisition of shares by a director is generally viewed positively, but it's not a market-moving event.

Positives

• The acquisition of shares by a director can be seen as a positive signal, indicating confidence in the company's future performance.

Future Outlook

The restricted stock units will be paid out in Abbott common shares upon the earlier of the director's separation from service, death, or a change in control.

Industry Context

Form 4 filings are routine disclosures required by the SEC to provide transparency regarding the transactions of company insiders. These filings are closely monitored by investors to gauge sentiment and potential future actions of key personnel.

Stakeholder Impact

• The acquisition of shares by a director can positively influence shareholder confidence.

Key Dates